Immuneering Corp

Company Profile

Immuneering Corp had its IPO on 2021-07-30 under the ticker symbol IMRX.

The company operates in the Healthcare sector and Biotechnology industry. Immuneering Corp has a staff strength of 66 employees.

Stock update

Shares of Immuneering Corp opened at $7.77 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.54 - $8.04, and closed at $7.73.

This is a -1.15% slip from the previous day's closing price.

A total volume of 48,192 shares were traded at the close of the day’s session.

In the last one week, shares of Immuneering Corp have slipped by -14.11%.

Immuneering Corp's Key Ratios

Immuneering Corp has a market cap of $263.38 million, indicating a price to book ratio of 1.1221 and a price to sales ratio of 238.4358.

In the last 12-months Immuneering Corp’s revenue was $38835 with a gross profit of $158830 and an EBITDA of $-55028748. The EBITDA ratio measures Immuneering Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Immuneering Corp’s operating margin was -142545.95% while its return on assets stood at -25.92% with a return of equity of -41.72%.

In Q2, Immuneering Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 99.8%.

Immuneering Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immuneering Corp’s profitability.

Immuneering Corp stock is trading at a EV to sales ratio of 48.2734 and a EV to EBITDA ratio of -0.5067. Its price to sales ratio in the trailing 12-months stood at 238.4358.

Immuneering Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$124.90 million

Total Liabilities

$5.48 million

Operating Cash Flow

$9.16 million

Capital Expenditure

$86686

Dividend Payout Ratio

0%

Immuneering Corp ended 2024 with $124.90 million in total assets and $0 in total liabilities. Its intangible assets were valued at $124.90 million while shareholder equity stood at $115.10 million.

Immuneering Corp ended 2024 with $0 in deferred long-term liabilities, $5.48 million in other current liabilities, 29263.00 in common stock, $-135579875.00 in retained earnings and $6.69 million in goodwill. Its cash balance stood at $104.02 million and cash and short-term investments were $108.99 million. The company’s total short-term debt was $332,675 while long-term debt stood at $0.

Immuneering Corp’s total current assets stands at $111.51 million while long-term investments were $0 and short-term investments were $4.97 million. Its net receivables were $743703.00 compared to accounts payable of $2.69 million and inventory worth $0.

In 2024, Immuneering Corp's operating cash flow was $9.16 million while its capital expenditure stood at $86686.

Comparatively, Immuneering Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$7.73

52-Week High

$16.167

52-Week Low

$3.7

Analyst Target Price

$19.29

Immuneering Corp stock is currently trading at $7.73 per share. It touched a 52-week high of $16.167 and a 52-week low of $16.167. Analysts tracking the stock have a 12-month average target price of $19.29.

Its 50-day moving average was $9.57 and 200-day moving average was $7.81 The short ratio stood at 48.19 indicating a short percent outstanding of 0%.

Around 2762.9% of the company’s stock are held by insiders while 4695.4% are held by institutions.